Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX Stock Report

Market Cap: US$3.5b

Crinetics Pharmaceuticals Management

Management criteria checks 3/4

Crinetics Pharmaceuticals' CEO is R. Struthers, appointed in Dec 2008, has a tenure of 16.08 years. total yearly compensation is $5.75M, comprised of 10.7% salary and 89.3% bonuses, including company stock and options. directly owns 1.09% of the company’s shares, worth $38.64M. The average tenure of the management team and the board of directors is 3.5 years and 4.3 years respectively.

Key information

R. Struthers

Chief executive officer

US$5.7m

Total compensation

CEO salary percentage10.7%
CEO tenure16.1yrs
CEO ownership1.1%
Management average tenure3.5yrs
Board average tenure4.3yrs

Recent management updates

Recent updates

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

Jan 02

We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Oct 02
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely

Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech

Aug 12

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

CEO Compensation Analysis

How has R. Struthers's remuneration changed compared to Crinetics Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$278m

Jun 30 2024n/an/a

-US$259m

Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$38m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$3mUS$410k

-US$27m

Compensation vs Market: R.'s total compensation ($USD5.75M) is about average for companies of similar size in the US market ($USD6.64M).

Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.

CEO

R. Struthers (61 yo)

16.1yrs

Tenure

US$5,747,994

Compensation

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

Leadership Team

NamePositionTenureCompensationOwnership
R. Struthers
Founder16.1yrsUS$5.75m1.09%
$ 38.6m
Stephen Betz
Founder & Chief Scientific Officer3.3yrsUS$2.50m0.024%
$ 856.1k
Marc J. Wilson
Chief Financial Officer7yrsUS$2.51m0.062%
$ 2.2m
Jeff Knight
Chief Operating Officer3.3yrsUS$2.36m0.0044%
$ 154.9k
Alan Krasner
Chief Endocrinologist6.6yrsUS$2.16m0.014%
$ 497.5k
Gayathri Diwakar
Head of Investor Relationsno datano datano data
Garlan Adams
General Counsel & Corporate Secretary3.6yrsno datano data
Adriana Cabre
Chief Human Resources Officer4.7yrsno datano data
Kevin Capps
Head of Intellectual Propertyno datano datano data
Chris Robillard
Chief Business Officer2.8yrsno datano data
Dana Pizzuti
Chief Medical & Development Officer2.3yrsUS$3.61m0.0058%
$ 205.2k
Robert Cuddihy
Senior Vice President of Medical Affairsless than a yearno datano data

3.5yrs

Average Tenure

59.5yo

Average Age

Experienced Management: CRNX's management team is considered experienced (3.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
R. Struthers
Founder16.2yrsUS$5.75m1.09%
$ 38.6m
Wendell Wierenga
Independent Chairman of the Board9.3yrsUS$375.31k0.11%
$ 4.0m
Matthew Fust
Independent Director6.9yrsUS$348.56k0.020%
$ 708.3k
Camille Bedrosian
Independent Director4.3yrsUS$339.56k0.0065%
$ 229.3k
Beverly M. Biller
Member of Scientific Advisory Boardno datano datano data
Rogerio Vivaldi Coelho
Independent Director3yrsUS$338.56k0.012%
$ 420.3k
Weston Nichols
Independent Director6.9yrsUS$338.56k0.0065%
$ 229.3k
Stephanie Okey
Independent Director5.5yrsUS$342.31k0.0065%
$ 229.3k
Caren Deardorf
Independent Director2.8yrsUS$330.06k0.0065%
$ 229.3k
Martin Heinrich Reincke
Member of Scientific Advisory Board2.8yrsno datano data
John Newell-Price
Member of Scientific Advisory Board2.8yrsno datano data
William Young
Member of Scientific Advisory Board2.8yrsno datano data

4.3yrs

Average Tenure

61yo

Average Age

Experienced Board: CRNX's board of directors are considered experienced (4.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/28 23:11
End of Day Share Price 2025/01/28 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Crinetics Pharmaceuticals, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Joshua SchimmerCantor Fitzgerald & Co.
Charles DuncanCantor Fitzgerald & Co.